Chinese Journal of Respiratory and Critical Care Medicine
Supervisor：Ministry of Education of the People's Republic of ChinaSponsor：West China Medical Center & West China Hospital, Sichuan University Editor-in-chief：LIN Jiangtao / LIU Chuntao Publishing period：
Monthly
ISSN：1671-6205CN：51-1631/R
Objective To observe the dynamic changes of plasma Clara cell secretory protein (CC16) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and to explore its role in the occurrence and development of the disease and clinical significance.Methods A total of 71 AECOPD patients were included in this study as observation group. All subjects completed the CAT questionnaire and were sampled 2 ml of venous blood on day 1 and day 7 after their admission. And the percentage of forced expiratory volume in the first second (FEV1%pred), percentage of forced vital capacity in the estimated value (FVC%pred), FEV1/FVC ratio, arterial partial pressure of carbon dioxide (PaCO2), white blood cell count (WBC), the proportion of neutrophils (NEUT%), C-reactive protein (CRP), procalcitonin (PCT) and the length of stay of subjects were recorded. Another 20 healthy adults were enrolled as the control group. Each subject of the control group was sampled 2 ml of venous blood. The plasma CC16 levels of the two groups were tested and compared, and analyzed its correlation with CAT score and length of stay.Results The plasma CC16 level of AECOPD patients was significantly lower than that of the control group, lung function was significantly lower than that of the healthy control group, WBC and NEUT% were significantly higher than that of the healthy control group, and the difference was statistically significant (P<0.05). Compared with day 1 after admission, the plasma CC16 level, CAT score, PaCO2, WBC, NEUT%, CRP, PCT of AECOPD patients on day 7 were significantly decreased, with statistically significant differences (P<0.05). The plasma CC16 level of AECOPD patients was negatively correlated with their CAT score (r=–0.704, P<0.001), and also was negatively correlated with the length of stay (r=–0.351, P=0.003).Conclusions CC16 is involved in the development and progression of AECOPD and closely related to the severity and prognosis of the disease. Its dynamic changes can predict the condition changes and evaluate the clinical treatment effect of patients with AECOPD. Combined with common clinical indicators, CC16 can shorten the length of stay of patients.
Citation：MA Qin, WANG Daoxin. Dynamic changes and clinical significance of plasma CC16 in patients with acute exacerbation of chronic obstructive pulmonary disease. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(2): 115-119. doi: 10.7507/1671-6205.201809025Copy
Copyright ? the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
1.
Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (2017 REPORT). http://goldcopd.org.
Celli BR, Owen CA. The club cell and its protein, CC16: time to shine. Lancet Respir Med, 2013, 1(10): 757-759.
4.
McAuley DF, Matthay MA. Clara cell protein CC16: a new lung epithelial biomarker for acute lung injury. Chest, 2009, 135(6): 1408-1410.
5.
Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy, 2000, 30(4): 469-475.
6.
Laucho-Contreras ME, Polverino F, Gupta K, et al. Protective role for club cell secretory protein-16 (CC16) in the development of COPD. Eur Respir, 2015, 45(6): 1544-1556.
7.
Long XB, Hu S, Wang N, et al. Clara cell 10-kDa protein gene transfection inhibits NF-kappaB activity in airway epithelial cells. PloS One, 2012, 7: e35960.
8.
Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC16 as a biomarker for COPD in the ECLIPSE cohort. Thorax, 2008, 63(12): 1058-1063.
9.
Zhu L, Di PY, Wu R, et al. Repression of CC16 by cigarette smoke (CS) exposure. PloS One, 2015, 10(1): e0116159.
10.
Petersen H, Leng S, Belinsky SA, et al. Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. Eur Respir J, 2015, 46(5): 1501-1503.
11.
Laucho-Contreras ME, Polverino F, Tesfaigzi Y, et al. Club cell protein 16 (CC16) augmentation: a potential disease-modifying approach for chronic obstructive pulmonary disease (COPD). Expert Opin Ther Targets, 2016, 20(7): 869-883.
12.
Park HY, Churg A, Wright J, et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2013, 188(12): 1413-1419.
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (2017 REPORT). http://goldcopd.org.
3. Celli BR, Owen CA. The club cell and its protein, CC16: time to shine. Lancet Respir Med, 2013, 1(10): 757-759.
4. McAuley DF, Matthay MA. Clara cell protein CC16: a new lung epithelial biomarker for acute lung injury. Chest, 2009, 135(6): 1408-1410.
5. Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy, 2000, 30(4): 469-475.
6. Laucho-Contreras ME, Polverino F, Gupta K, et al. Protective role for club cell secretory protein-16 (CC16) in the development of COPD. Eur Respir, 2015, 45(6): 1544-1556.
7. Long XB, Hu S, Wang N, et al. Clara cell 10-kDa protein gene transfection inhibits NF-kappaB activity in airway epithelial cells. PloS One, 2012, 7: e35960.
8. Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC16 as a biomarker for COPD in the ECLIPSE cohort. Thorax, 2008, 63(12): 1058-1063.
9. Zhu L, Di PY, Wu R, et al. Repression of CC16 by cigarette smoke (CS) exposure. PloS One, 2015, 10(1): e0116159.
10. Petersen H, Leng S, Belinsky SA, et al. Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. Eur Respir J, 2015, 46(5): 1501-1503.
11. Laucho-Contreras ME, Polverino F, Tesfaigzi Y, et al. Club cell protein 16 (CC16) augmentation: a potential disease-modifying approach for chronic obstructive pulmonary disease (COPD). Expert Opin Ther Targets, 2016, 20(7): 869-883.
12. Park HY, Churg A, Wright J, et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2013, 188(12): 1413-1419.
Click the content below to copy and paste a set citation format。
Citation：MA Qin, WANG Daoxin. Dynamic changes and clinical significance of plasma CC16 in patients with acute exacerbation of chronic obstructive pulmonary disease. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(2): 115-119. doi: 10.7507/1671-6205.201809025
1/5
WeChat